Skip to main content
Caplight Logo









ATANIS Biotech AG

ATANIS Biotech AG

Private
BernHealthcare & Life Scienceshttps://www.atanis-biotech.com/

Last Round

Grant

Feb 20, 2025

Total Funding Raised

$2M

Company Overview

ATANIS Biotech AG is a biotechnology company that develops a novel, cell-based allergy diagnostic assay called FAST-PASE® to safely and accurately assess allergic reactions in a test tube.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

allergy diagnosticsmast cell activationex vivo assayoral food challengeOFCfood allergy testingbiomarker developmentpreclinical researchallergenicity assessmentcontract researchCROdrug discoverylab-based testingallergy lab

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ATANIS Biotech AG Comparables

Compare ATANIS Biotech AG with similar companies based on industry and business-model similarity.

ATANIS Biotech AG comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AllerGenis
77%
Eurofins Scientific SE
72%
BÜHLMANN Laboratories AG
71%

ATANIS Biotech AG Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 20, 2025
Early FundingOct 22, 2024
Early FundingMar 28, 2023

Key People

Founding team and executive leadership

Jean-Pierre Kinet

Chief Executive Officer, Founder and Chairman

Founding Team

Erwan Eriau

Chief Operating Officer

Executive Team

Jonathan Friedlander

Chief Business Officer

Executive Team

ATANIS Biotech AG Investors

Notable investors and investment history

ATANIS Biotech AG investors
InvestorRounds
AllerFundEarly Funding
Spectrum Moonshot FundEarly Funding
iXLife CapitalEarly Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 11, 2025

    Grew 27% QoQ, from 22 to 28 employees.

  • May 1, 2025

    Grew 21% QoQ, from 19 to 23 employees.

ATANIS Biotech AG Filings

Explore SEC and related filing metadata, where available.

ATANIS Biotech AG filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ATANIS Biotech AG's valuation, stock price, and market status.

Is ATANIS Biotech AG a public or private company?

ATANIS Biotech AG is a private company.

What is the current stock price of ATANIS Biotech AG?

ATANIS Biotech AG is a private company with no public stock price. No recent secondary market data is available.

How much is ATANIS Biotech AG worth (valuation)?

Valuation information for ATANIS Biotech AG is not publicly available.

Can I buy ATANIS Biotech AG stock?

ATANIS Biotech AG shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ATANIS Biotech AG's last funding round?

ATANIS Biotech AG's most recent funding round was Grant on February 20, 2025.

Who are the main investors in ATANIS Biotech AG?

Key investors in ATANIS Biotech AG include AllerFund, Spectrum Moonshot Fund.

Will ATANIS Biotech AG IPO soon?

No public IPO plans have been announced for ATANIS Biotech AG.

How can I track ATANIS Biotech AG secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ATANIS Biotech AG's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBern
Employee Range21
Year Founded2021
Last FundingFeb 20, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?